Omega Therapeutics Q2 EPS $(0.54) Misses $(0.51) Estimate, Sales $759.00K Beat $450.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Omega Therapeutics (NASDAQ:OMGA) reported Q2 losses of $(0.54) per share, missing the analyst consensus estimate of $(0.51) by 5.88%. However, the company's quarterly sales of $759.00K beat the analyst consensus estimate of $450.00K by 68.67%, marking a 59.45% increase over the same period last year.
August 04, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Omega Therapeutics' Q2 earnings per share missed estimates, but sales exceeded expectations and showed significant YoY growth.
While the company's earnings per share fell short of estimates, which could negatively impact the stock, the significant beat on sales and YoY growth could offset this impact, leading to a neutral short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100